tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Arita C et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. 1990 Clin. Exp. Immunol. pmid:1702374
Woo J et al. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. 1990 Clin. Exp. Immunol. pmid:1702375
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. 1991 Transplant. Proc. pmid:1721253
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Schreiber SL Chemistry and biology of the immunophilins and their immunosuppressive ligands. 1991 Science pmid:1702904
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Wasik M et al. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. 1991 Transplantation pmid:1702910
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Ziccardi VB et al. Maxillofacial considerations in orthotopic liver transplantation. 1991 Oral Surg. Oral Med. Oral Pathol. pmid:1704494
Bierer BE et al. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. 1991 Eur. J. Immunol. pmid:1705513
Heitman J et al. FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1705713
Goebl MG The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. 1991 Cell pmid:1706222
de Paulis A et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. 1991 J. Immunol. pmid:1706398
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Davies CB et al. Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. 1991 Transplant. Proc. pmid:1721448
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Francavilla A et al. Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. 1991 Hepatology pmid:1712337
Aoki H [FK 506, a new immunosuppressant produced by a Streptomyces]. 1991 Nippon Rinsho pmid:1712403
Hultsch T et al. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1712484
Weaver JL et al. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. 1991 Immunopharmacol Immunotoxicol pmid:1723084
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
Burres NS et al. Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. 1991 J. Antibiot. pmid:1723403
Nielsen JB et al. Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. 1991 Biochemistry pmid:2043618
McKeon F When worlds collide: immunosuppressants meet protein phosphatases. 1991 Cell pmid:1716181
Petros AM et al. NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. 1991 J. Med. Chem. pmid:1716684
FK 506--an investigational immunosuppressant. 1991 Med Lett Drugs Ther pmid:1716722
Ochiai T et al. [Immunosuppressive agents--advances of the developmental studies and the mode of action]. 1991 Nippon Rinsho pmid:1715926
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Liu J et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. 1991 Cell pmid:1715244
Henderson DJ et al. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. 1991 Immunology pmid:1715317
DeFranco AL Signal transduction. Immunosuppressants at work. 1991 Nature pmid:1715515
Flanagan WM et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. 1991 Nature pmid:1715516
McWhinnie DL and Morris PJ Combination drug therapies for immunosuppression in transplantation. 1991 Ann. Acad. Med. Singap. pmid:1724724